{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.0","upperLimit":"24.9","value":"19.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"}],"units":"Participants"}],"description":"Objective Response Rate (ORR) was defined as the number of participants with a best overall response of confirmed Complete Response (CR) or Partial Response (PR) (per RECIST 1.1 criteria) divided by the number of all treated participants. RECIST 1.1 = Response Evaluation Criteria in Solid Tumors. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. BIRC= blinded independent review committee","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg was administered as a 60 minute IV infusion Q2W","id":"OG000","title":"Nivolumab 3 mg/kg"}],"paramType":"NUMBER","populationDescription":"All treated participants. Treated participants from Japan enrolled after main enrollment period were excluded from primary efficacy analysis.","reportingStatus":"POSTED","timeFrame":"From the date of first dose to the date of objectively documented progression or the date of subsequent therapy, whichever occurs first (assessed up to 14 months)","title":"Objective Response Rate Per BIRC Assessment","type":"PRIMARY","unitOfMeasure":"Percent of participants"}